Changes in the board at Isofol Medical AB (publ)
Gothenburg, Sweden, June 7, 2023 – Isofol Medical AB (publ) announces today that its Board of Directors has appointed Anders Edvell as a co-opted member of the Board. This is following the resignation of Jan-Eric Österlund, who today has decided to resign as Board Director and instead will take a new role as senior advisor to the company.
The information in the press release is intended for investors.
The board has decided to co-opt Anders Edvell to the board of Isofol. Anders Edvell has over 20 years of experience in the pharmaceutical industry and is currently CEO of Immedica Pharma, a pharmaceutical company focused on commercialization of medicines for rare diseases and special diseases. He has previously been CEO at Unimedic Pharma, VP Global Product Strategies and Head of Partner Products at Sobi, Country Manager at Swedish Orphan, and held several leading medical roles at Bristol-Myers Squibb and Recip.
"We are pleased to welcome Anders Edvell as a co-opted in Isofol's Board of Directors. His solid background in the pharmaceutical industry will be extremely valuable in the company's continued value creation. We are also grateful that Jan-Eric Österlund will continue to contribute with his expertise, but now as an external advisor to the company," says Mats Franzén, Chairman of the Board, Isofol.
For more information, please contact
Isofol Medical AB (publ)
Mats Franzén, chairman of the board
E-post: [email protected]
The information was submitted for publication, through the agency of the contact person set out above, at 17:55 CEST on June 7, 2023.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
